DE1792053B1 - Brandsalbe - Google Patents
BrandsalbeInfo
- Publication number
- DE1792053B1 DE1792053B1 DE19681792053 DE1792053A DE1792053B1 DE 1792053 B1 DE1792053 B1 DE 1792053B1 DE 19681792053 DE19681792053 DE 19681792053 DE 1792053 A DE1792053 A DE 1792053A DE 1792053 B1 DE1792053 B1 DE 1792053B1
- Authority
- DE
- Germany
- Prior art keywords
- silver
- ointment
- sulfadiazine
- burn
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002674 ointment Substances 0.000 title claims description 44
- SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 claims description 59
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 claims description 36
- 239000000243 solution Substances 0.000 claims description 34
- 229960003600 silver sulfadiazine Drugs 0.000 claims description 33
- 229960004306 sulfadiazine Drugs 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- GGCZERPQGJTIQP-UHFFFAOYSA-N sodium;9,10-dioxoanthracene-2-sulfonic acid Chemical compound [Na+].C1=CC=C2C(=O)C3=CC(S(=O)(=O)O)=CC=C3C(=O)C2=C1 GGCZERPQGJTIQP-UHFFFAOYSA-N 0.000 claims description 20
- 238000011282 treatment Methods 0.000 claims description 20
- 229910001961 silver nitrate Inorganic materials 0.000 claims description 18
- 239000004332 silver Substances 0.000 claims description 17
- 229910052709 silver Inorganic materials 0.000 claims description 17
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims description 16
- 239000003883 ointment base Substances 0.000 claims description 13
- 150000001875 compounds Chemical class 0.000 claims description 11
- 238000002474 experimental method Methods 0.000 claims description 9
- 241000699670 Mus sp. Species 0.000 claims description 8
- 208000002193 Pain Diseases 0.000 claims description 8
- 230000036407 pain Effects 0.000 claims description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- 239000000839 emulsion Substances 0.000 claims description 6
- 208000015181 infectious disease Diseases 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims description 5
- 210000002700 urine Anatomy 0.000 claims description 5
- 239000007764 o/w emulsion Substances 0.000 claims description 4
- 239000000725 suspension Substances 0.000 claims description 4
- 101710134784 Agnoprotein Proteins 0.000 claims description 3
- 230000037396 body weight Effects 0.000 claims description 3
- 235000019271 petrolatum Nutrition 0.000 claims description 3
- 238000001556 precipitation Methods 0.000 claims description 3
- 229940100890 silver compound Drugs 0.000 claims description 3
- 150000003379 silver compounds Chemical class 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- PAVKBQLPQCDVNI-UHFFFAOYSA-N n',n'-diethyl-n-(9-methoxy-5,11-dimethyl-6h-pyrido[4,3-b]carbazol-1-yl)propane-1,3-diamine Chemical compound N1C2=CC=C(OC)C=C2C2=C1C(C)=C1C=CN=C(NCCCN(CC)CC)C1=C2C PAVKBQLPQCDVNI-UHFFFAOYSA-N 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 150000005846 sugar alcohols Polymers 0.000 claims description 2
- 231100000331 toxic Toxicity 0.000 claims description 2
- 230000002588 toxic effect Effects 0.000 claims description 2
- 206010070863 Toxicity to various agents Diseases 0.000 claims 2
- 238000002513 implantation Methods 0.000 claims 2
- 241000282472 Canis lupus familiaris Species 0.000 claims 1
- 230000036765 blood level Effects 0.000 claims 1
- 230000034994 death Effects 0.000 claims 1
- 231100000517 death Toxicity 0.000 claims 1
- 239000007928 intraperitoneal injection Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- NBYLLBXLDOPANK-UHFFFAOYSA-M silver 2-carboxyphenolate hydrate Chemical compound C1=CC=C(C(=C1)C(=O)O)[O-].O.[Ag+] NBYLLBXLDOPANK-UHFFFAOYSA-M 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 239000010414 supernatant solution Substances 0.000 claims 1
- 231100000419 toxicity Toxicity 0.000 claims 1
- 230000001988 toxicity Effects 0.000 claims 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 30
- 229940124530 sulfonamide Drugs 0.000 description 22
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 16
- 238000002560 therapeutic procedure Methods 0.000 description 16
- 239000011780 sodium chloride Substances 0.000 description 15
- 150000003456 sulfonamides Chemical class 0.000 description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 230000000844 anti-bacterial effect Effects 0.000 description 8
- 239000007795 chemical reaction product Substances 0.000 description 8
- 239000011734 sodium Substances 0.000 description 8
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 7
- 206010052428 Wound Diseases 0.000 description 7
- 208000027418 Wounds and injury Diseases 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 239000003792 electrolyte Substances 0.000 description 7
- 229910052708 sodium Inorganic materials 0.000 description 7
- TYMRLRRVMHJFTF-UHFFFAOYSA-N Mafenide Chemical compound NCC1=CC=C(S(N)(=O)=O)C=C1 TYMRLRRVMHJFTF-UHFFFAOYSA-N 0.000 description 6
- 210000001124 body fluid Anatomy 0.000 description 6
- 239000010839 body fluid Substances 0.000 description 6
- 229960003640 mafenide Drugs 0.000 description 6
- -1 p-aminobenzene sulfone Chemical class 0.000 description 6
- 150000003378 silver Chemical class 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 5
- 238000001228 spectrum Methods 0.000 description 5
- 125000003396 thiol group Chemical group [H]S* 0.000 description 5
- 238000000862 absorption spectrum Methods 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000589516 Pseudomonas Species 0.000 description 3
- 229910021607 Silver chloride Inorganic materials 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 3
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 3
- SIACJRVYIPXFKS-UHFFFAOYSA-N (4-sulfamoylphenyl)methylazanium;chloride Chemical compound Cl.NCC1=CC=C(S(N)(=O)=O)C=C1 SIACJRVYIPXFKS-UHFFFAOYSA-N 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 208000010444 Acidosis Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 102000011782 Keratins Human genes 0.000 description 2
- 108010076876 Keratins Proteins 0.000 description 2
- 208000032536 Pseudomonas Infections Diseases 0.000 description 2
- 206010039509 Scab Diseases 0.000 description 2
- 206010053615 Thermal burn Diseases 0.000 description 2
- 230000007950 acidosis Effects 0.000 description 2
- 208000026545 acidosis disease Diseases 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 229960000603 cefalotin Drugs 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000000622 irritating effect Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229960005181 morphine Drugs 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229960002211 sulfapyridine Drugs 0.000 description 2
- 229960001544 sulfathiazole Drugs 0.000 description 2
- 239000002023 wood Substances 0.000 description 2
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical class OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010020852 Hypertonia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108050004689 Inhibitor of carbonic anhydrases Proteins 0.000 description 1
- 206010028116 Mucosal inflammation Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical class N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- FOIXSVOLVBLSDH-UHFFFAOYSA-N Silver ion Chemical compound [Ag+] FOIXSVOLVBLSDH-UHFFFAOYSA-N 0.000 description 1
- 206010041925 Staphylococcal infections Diseases 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000005005 aminopyrimidines Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 150000008331 benzenesulfonamides Chemical class 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- XIURVHNZVLADCM-IUODEOHRSA-N cefalotin Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C(O)=O)C(=O)CC1=CC=CS1 XIURVHNZVLADCM-IUODEOHRSA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960003346 colistin Drugs 0.000 description 1
- 238000002485 combustion reaction Methods 0.000 description 1
- 239000012084 conversion product Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 230000000774 hypoallergenic effect Effects 0.000 description 1
- 239000000815 hypotonic solution Substances 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 230000001530 keratinolytic effect Effects 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 229940125722 laxative agent Drugs 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- SFDJOSRHYKHMOK-UHFFFAOYSA-N nitramide Chemical class N[N+]([O-])=O SFDJOSRHYKHMOK-UHFFFAOYSA-N 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229940083025 silver preparation Drugs 0.000 description 1
- OGFYIDCVDSATDC-UHFFFAOYSA-N silver silver Chemical compound [Ag].[Ag] OGFYIDCVDSATDC-UHFFFAOYSA-N 0.000 description 1
- AUNMWCHVALXUIJ-UHFFFAOYSA-N silver sodium dinitrate Chemical compound [Na+].[Ag+].[O-][N+]([O-])=O.[O-][N+]([O-])=O AUNMWCHVALXUIJ-UHFFFAOYSA-N 0.000 description 1
- HMYODOSAWROGPE-UHFFFAOYSA-N silver;4-amino-n-(5-methyl-1,3,4-thiadiazol-2-yl)benzenesulfonamide Chemical compound [Ag+].S1C(C)=NN=C1NS(=O)(=O)C1=CC=C(N)C=C1 HMYODOSAWROGPE-UHFFFAOYSA-N 0.000 description 1
- 231100000075 skin burn Toxicity 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- GRVFOGOEDUUMBP-UHFFFAOYSA-N sodium sulfide (anhydrous) Chemical compound [Na+].[Na+].[S-2] GRVFOGOEDUUMBP-UHFFFAOYSA-N 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229960002597 sulfamerazine Drugs 0.000 description 1
- 229940091629 sulfamylon Drugs 0.000 description 1
- PGWMQVQLSMAHHO-UHFFFAOYSA-N sulfanylidenesilver Chemical compound [Ag]=S PGWMQVQLSMAHHO-UHFFFAOYSA-N 0.000 description 1
- GECHUMIMRBOMGK-UHFFFAOYSA-N sulfapyridine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=CC=CC=N1 GECHUMIMRBOMGK-UHFFFAOYSA-N 0.000 description 1
- 229960001975 sulfisomidine Drugs 0.000 description 1
- 125000000565 sulfonamide group Chemical group 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000008256 whipped cream Substances 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/38—Silver; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65383067A | 1967-07-17 | 1967-07-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE1792053B1 true DE1792053B1 (de) | 1971-07-29 |
Family
ID=24622450
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19681792053 Pending DE1792053B1 (de) | 1967-07-17 | 1968-07-17 | Brandsalbe |
Country Status (8)
| Country | Link |
|---|---|
| BE (1) | BE718183A (enrdf_load_stackoverflow) |
| DE (1) | DE1792053B1 (enrdf_load_stackoverflow) |
| ES (1) | ES356142A1 (enrdf_load_stackoverflow) |
| FR (2) | FR1586125A (enrdf_load_stackoverflow) |
| GB (2) | GB1240545A (enrdf_load_stackoverflow) |
| IE (1) | IE32197B1 (enrdf_load_stackoverflow) |
| NL (1) | NL6809794A (enrdf_load_stackoverflow) |
| PH (1) | PH10639A (enrdf_load_stackoverflow) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2424740A1 (fr) * | 1978-02-06 | 1979-11-30 | Fresenius Chem Pharm Ind | Sels metalliques de sulfadiazine en fines particules, leur procede de preparation et preparations pharmaceutiques les contenant |
| US4384117A (en) * | 1980-03-18 | 1983-05-17 | The United States Of America As Represented By The Secretary Of The Army | Silver metachloridine |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4049802A (en) | 1975-03-19 | 1977-09-20 | Research Corporation | Zinc sulfadiazine and its use in the treatment of burns |
| US4933330A (en) * | 1987-04-01 | 1990-06-12 | Dak-Laboratoriet | Benzoic acid derivatives and use thereof |
| CA2024220A1 (en) * | 1990-08-29 | 1992-03-01 | Don Simmons | Composition containing silver sulfadiazine and benzocaine for use in the treatment of wounds following laser surgery |
| IT1243435B (it) * | 1990-10-05 | 1994-06-10 | Altergon Sa | Composizioni farmaceutiche per uso topico comprendenti acido ialuronico sale sodico e sostanze disinfettanti |
| US7074788B2 (en) | 2001-11-22 | 2006-07-11 | Biovitrum Ab | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
| EP1631558A1 (en) * | 2003-05-21 | 2006-03-08 | Biovitrum Ab | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type i |
| US7173030B2 (en) | 2003-05-21 | 2007-02-06 | Biovitrum Ab | Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 |
| SE0301882D0 (sv) * | 2003-06-25 | 2003-06-25 | Biovitrum Ab | New use I |
| SE0301886D0 (sv) * | 2003-06-25 | 2003-06-25 | Biovitrum Ab | New use V |
| SE0301884D0 (sv) * | 2003-06-25 | 2003-06-25 | Biovitrum Ab | New use III |
| SE0301888D0 (sv) * | 2003-06-25 | 2003-06-25 | Biovitrum Ab | New use VII |
| SE0301885D0 (sv) * | 2003-06-25 | 2003-06-25 | Biovitrum Ab | New use IV |
| WO2004113310A1 (en) * | 2003-06-25 | 2004-12-29 | Biovitrum Ab | Use of an inhibitor of 11-b-hydroxysteroid dehydrogenase type 1 compounds for promoting wound healing |
| BRPI1104620B1 (pt) * | 2011-09-09 | 2020-04-07 | Lucia Teixeira De Carvalho | composição farmacêutica para tratamento de queimaduras e lesões da pele e seu processo de preparação |
-
1968
- 1968-07-05 PH PH9358A patent/PH10639A/en unknown
- 1968-07-10 NL NL6809794A patent/NL6809794A/xx unknown
- 1968-07-13 ES ES356142A patent/ES356142A1/es not_active Expired
- 1968-07-15 IE IE83968A patent/IE32197B1/xx unknown
- 1968-07-16 GB GB33831/68A patent/GB1240545A/en not_active Expired
- 1968-07-16 GB GB4945970A patent/GB1240546A/en not_active Expired
- 1968-07-16 FR FR1586125D patent/FR1586125A/fr not_active Expired
- 1968-07-17 BE BE718183D patent/BE718183A/xx not_active IP Right Cessation
- 1968-07-17 DE DE19681792053 patent/DE1792053B1/de active Pending
- 1968-10-11 FR FR169591A patent/FR8146M/fr not_active Expired
Non-Patent Citations (1)
| Title |
|---|
| None * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2424740A1 (fr) * | 1978-02-06 | 1979-11-30 | Fresenius Chem Pharm Ind | Sels metalliques de sulfadiazine en fines particules, leur procede de preparation et preparations pharmaceutiques les contenant |
| US4384117A (en) * | 1980-03-18 | 1983-05-17 | The United States Of America As Represented By The Secretary Of The Army | Silver metachloridine |
Also Published As
| Publication number | Publication date |
|---|---|
| PH10639A (en) | 1977-07-22 |
| FR1586125A (enrdf_load_stackoverflow) | 1970-02-13 |
| ES356142A1 (es) | 1970-02-16 |
| FR8146M (enrdf_load_stackoverflow) | 1970-08-17 |
| IE32197L (en) | 1969-01-17 |
| GB1240545A (en) | 1971-07-28 |
| BE718183A (enrdf_load_stackoverflow) | 1969-01-17 |
| NL6809794A (enrdf_load_stackoverflow) | 1969-01-21 |
| IE32197B1 (en) | 1973-05-16 |
| GB1240546A (en) | 1971-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60032543T2 (de) | Topisch verabreichbare Zinkzusammensetzungen | |
| DE69923987T2 (de) | Synergistische antimikrobielle, dermatologische und ophtahalmologische zubereitung, die ein chlorit und wasserstoffperoxid enthalten | |
| EP0700249B1 (de) | Antiinfektivum | |
| DE69709682T2 (de) | Gruene salbe | |
| EP0026532B1 (de) | Haut- und Schleimhautpräparat, Verfahren zu seiner Herstellung und Mittel zur Durchführung des Verfahrens | |
| DE1792053B1 (de) | Brandsalbe | |
| DE2611725A1 (de) | Zinksulfadiazin und dieses enthaltende dermatotherapeutische mittel zur behandlung von verbrennungen | |
| DE2736777A1 (de) | Verspruehbare keimtoetende schaum- zusammensetzungen | |
| DE3032481A1 (de) | Praeparat zur therapeutischen und/oder kosmetischen anwendung an lebewesen | |
| DE3014524A1 (de) | Wundheilmittel | |
| EP0308436B1 (de) | Neue heilsalbe, verfahren zu ihrer herstellung, unter verwendung dieser heilsalbe hergestellte applikationsformen sowie deren herstellung | |
| JP6899872B2 (ja) | 次亜塩素酸ナトリウムを含む抗炎症溶液 | |
| EP0103878A2 (de) | Präparate zur Behandlung von Wunden der Hautoberfläche und Verfahren zur Herstellung derartiger Präparate | |
| DE2709121C2 (enrdf_load_stackoverflow) | ||
| RU2177314C2 (ru) | Состав с антисептическими, репаративными и болеутоляющими свойствами | |
| DE1792053C (de) | Brandsalbe | |
| EP1135116A1 (de) | Verwendung von poly (hexamethylen) biguanid zur herstellung eines mittels zur förderung der heilung von infektionsfreien wunden | |
| JP3127289B2 (ja) | 外用の抗真菌性及び殺虫性生成物 | |
| AT412448B (de) | Verwendung von selenhältigen präparaten | |
| DE2130775A1 (de) | Mittel zur Behandlung von Dermatosen | |
| AT290016B (de) | Verfahren zur Herstellung einer Brandsalbe | |
| DE3520325C2 (enrdf_load_stackoverflow) | ||
| DE69716769T2 (de) | Zubereitungen zur behandlung von verbrennungen und externen ulcera sowie verfahren zu deren herstellung | |
| RU2216327C2 (ru) | Способ лечения и профилактики саркоптоидозов и демодекозов животных | |
| EP1880713A1 (de) | Verwendung einer Zubereitung aus Calciumhydroxid und Öl zur Hautwundversorgung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E77 | Valid patent as to the heymanns-index 1977 |